Skip to Main Content

Paper Details

Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review.
JAMA Cardiol
15
2022
AF, VTE, apixaban, aspirin, atherosclerotic vascular disease, atrial fibrillation, cancer, dabigatran, edoxaban, patients, peripheral artery disease, rivaroxaban, stroke, venous thromboembolism
Author NameAffiliation
Renato D LopesDuke Clinical Research Institute, Duke University Medical Center
Renato D LopesBrazilian Clinical Research Institute
Deepak L BhattBrigham and Women's Hospital, Harvard Medical School
Roxana MehranZena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai
Harlan M KrumholzYale New Haven Hospital/Yale Center for Outcomes Research and Evaluation
Harlan M KrumholzYale School of Public Health
Harlan M KrumholzYale School of Medicine
Harlan M KrumholzYale New Haven Hospital/Yale Center for Outcomes Research and Evaluation
Harlan M KrumholzYale School of Public Health
Harlan M KrumholzYale School of Medicine
  • 1 - 10

Datasets

Release 1.2